相关实验视频

Updated: Jul 28, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

系统性乳腺细胞瘤:2023年成人诊断和管理的更新

Alessandro Costa¹, Emilia Scalzulli², Ida Carmosino²

¹Hematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Expert opinion on emerging drugs

|May 31, 2023

概括

世界卫生组织和ICC最近对系统性乳腺细胞瘤 (SM) 诊断标准的更新改善了分类. 新的向疗法为先进的MS提供了改进的治疗策略,临床试验中的新型抑制剂.

科学领域:

血液学血液学血液学
在瘤学瘤学.
内部医学内部医学

背景情况:

系统性乳腺细胞瘤 (SM) 是一种异质的克隆性乳腺细胞疾病.
世界卫生组织 (WHO) 和国际共识分类 (ICC) 最近的2022年更新修改了SM诊断和分类标准.
鉴定临床和分子变量的进步提高了预后工具和个性化治疗方法.

研究的目的:

审查国际共识分类 (ICC) 引入的SM诊断标准更新.
提供最新的临床试验数据,用于非晚期和晚期全身性巨细胞瘤患者.
讨论新兴的向疗法,包括elenestinib和 bezuclastinib.

主要方法:

审查最近的文献和临床试验数据.
分析了世卫组织和ICC最新的诊断和分类标准.
综合有关新型向疗法和下一代抑制剂的信息.

主要成果:

2022年世卫组织和ICC分类为SM提供了一个简化和更清晰的诊断方案.
已批准的向疗法,如midostaurin和avapritinib,已经改变了高级MS的治疗范式.
目前正在进行的临床试验正在研究下一代抑制剂,有望在未来的治疗方面取得进展.

结论:

更新的诊断标准提高了系统性乳腺细胞瘤的处理.
新的向疗法显著改善了晚期SM患者的治疗结果.
预计未来的研究和临床试验将在SM治疗方面取得进一步的进展.

关键词:

国际刑事法庭国际刑事法庭国际刑事法庭国际刑事法庭系统性乳腺细胞结核病.这就是阿瓦普里提尼布.贝兹克拉斯蒂尼布的使用方法埃伦尼斯特尼布 (Elenestinib) 是一个非常重要的药物.氨酸激酶抑制剂氨酸激酶抑制剂

更多相关视频

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

相关概念视频

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...